In recent years, access to information regarding acquisition and synthesis of newer designer drugs has been at an all-time high due largely to the Internet. As these drugs have become more prevalent, laboratory techniques have been developed and refined to identify and screen for this burgeoning population of drugs. This provides a unique opportunity for learning about many of these methods. Laboratory testing techniques and instrumentation are obscure to many health care professionals, yet their results are crucial. Here, we present a case of an overdose of an uncommon designer drug (2C-E) and discuss the basics of liquid chromatography and mass spectrometry, two important techniques used in isolating and identifying the drug. Although often overlooked and taken for granted, these techniques can play a pivotal role in the diagnosis and subsequent management of select patients.
T he drug scene is constantly changing and evolving. Traditionally, drugs of abuse are associated with popular street drugs such as marijuana, heroin, cocaine, and methamphetamine. In the 1990s, several other drugs were added to this list, including the so-called "club drugs": ecstasy, ketamine, and gamma hydroxybutyric acid. In more recent years, "designer drugs" have emerged, which are either chemically altered natural substances or completely synthetic molecular structures that have psychotropic eff ects. Due to the widespread use of the Internet, information regarding synthesis of and access to novel compounds is more accessible than ever. Th is poses new challenges to the medical community in terms of treatment as well as identifi cation of the abused substance, especially in patients unable to communicate. Here we present a case of a fatal overdose of the designer drug known as 2C-E (4-ethyl-2, 5-dimethoxy-β-phenethylamine), a phenethylamine derivative. Although previously published, the prior case report focused on radiographic fi ndings (1) . In the present article, we focus on how 2C-E is detected in the urine using basic chromatography and mass spectrometry principles.
CASE REPORT
A 26-year-old white man with known polysubstance abuse and psychiatric problems was found unresponsive at a friend's house. Initial emergency responders intubated the patient and treated him with naloxone with no change in clinical status. According to the patient's friend, he had ingested a drug known as 2C-E, but was not aware of any other drug or alcohol use. Th e patient had prescriptions for various psychiatric medications including sertraline, clonazepam, gabapentin, and zolpidem.
In the emergency department, his clinical status remained unchanged. An initial urine toxicology screen was positive for marijuana metabolites and benzodiazepines. A head computed tomography scan was negative, and electroencephalography showed diff use slowing. Th e patient's initial laboratory studies are shown in Table 1 .
On admission, the patient had acute kidney failure and leukocytosis, and he subsequently developed a right lower lobe pneumonia, which resolved with antibiotics. Although the patient remained obtunded, his brain stem refl exes remained intact throughout his hospitalization. After discussing the patient's prognosis in detail, the family decided to withdraw lifesupporting therapy. Th e patient died about 2 weeks after his initial admission. Subsequent specialized urine drug screens were positive for the compound known as 2C-E.
DISCUSSION
Th e 2C family of designer drugs is a large group of chemicals classifi ed as ring-substituted phenethylamines, most of which were fi rst synthesized in the 1970s by the chemist Alexander Shulgin (2) . Th ey are characterized by methoxy groups at positions 2 and 5 of the benzene ring. Within the 2C family, there are diff erences in the substitution of the fourth position on the benzene ring. For instance, at position 4, 2C-I substitutes iodine while 2C-B substitutes bromine. For 2C-E in particular, an ethyl group is substituted at position 4 ( Figure 1) . A full list of 2C compounds published by Shulgin is provided in Table 2 .
Pharmacologically, 2C-E (and the 2C family) shows strong effi cacy for the 5-HT 2C receptor, accounting for its hallucinogenic eff ects (3). Accounts from users typically report a dosage range from 10 to 30 mg (2) . Although little is known of the pharmacokinetics of the drug, it seemingly takes eff ect within seconds of insuffl ation, with a slightly delayed action if taken orally. Th e drug displays a marked dosage eff ect, and hallucinogenic activity typically lasts for 4 to 8 hours (2). Metabolism of 2C-E appears to have several pathways, although the main ones appear to be via hepatic oxidative deamination and/or O-demethylation (4) (5) (6) .
Th e clinical presentation of users of the 2C group can be varied. At lower doses, the drugs act as a stimulant (2) . However, at higher doses (>10 mg), there is a marked hallucinogenic and psychoactive eff ect. Deaths have also been reported following the usage of 2C compounds including, but not limited to, 2C-T-7 (7) and 2C-I (8).
For diagnosis, an analytic method for detection and quantifi cation is required for clinical chemistry and forensic toxicology. Many diff erent techniques have been developed to screen for these newer designer drugs, including capillary electrophoresismass spectrometry (9) (10) (11) (12) , capillary electrophoresis coupled with a diode array detector (13), gas chromatography-mass spectrometry (14, 15) , and liquid chromatography-mass spectrometry (LC-MS) (16) . In more recent years, LC-MS in tandem (LC-MS/MS) has become the detection test of choice due to its ability to separate and identify small molecules with similar structures in one run (17) .
In order to understand LC-MS/MS, it is easiest to break it up into its separate analytic components. The liquid chromatography phase, specifi cally high-performance liquid chromatography, separates chemicals by running a solvent Identification of designer drug 2C-E in urine following a drug overdose January 2013(mobile phase) containing the chemicals of interest through a column (stationary phase). Th e chemical (2C-E) binds to the column through hydrophobic interactions. As can be expected, diff erent molecules elute through the column at diff erent times due to diff erences in molecular structure and hydrophobic interactions. Th is technique is very good at separating chemicals (even molecules with very similar masses); however, it does not necessarily identify the compound, especially if there are many unknown chemicals in the sample. Th is is where coupling of mass spectrometry is useful.
In typical non-tandem mass spectrometry, these unknown compounds enter the mass spectrometer, where they are initially ionized and given either a positive or a negative charge. Mass spectrometers identify the molecules present in a sample based on their mass-to-charge ratio (m/z). Th e molecules then move into the quadrapole chamber, which consists of four parallel magnetic rods arranged in a square formation (Figure 2 ) (18) . Th e rods are calibrated in such a way that only the ions of interest are allowed to pass unimpeded through the chamber and hit the detector. For instance, 2C-E has a molecular weight of approximately 209 and a charge of 1+ following ionization; therefore, the m/z ratio will be 209. Th e mass spectrometer only allows compounds with this specifi c m/z ratio to pass through and be detected. However, other compounds can have very similar m/z ratios, detracting from the specifi city of a mass spectrometer. For example, morphine and hydromorphine have an identical m/z ratio of 286, thus making separation of the two compounds diffi cult by non-tandem mass spectrometry. Running mass spectrometry in tandem can help alleviate this issue.
Mass spectrometry in tandem is characterized by multiple quadrapoles (typically three) that are arranged in a series (Figure 3) (18) . Th e fi rst and third quadrapoles are similar in function to those described previously. Th e middle quadrapole differs in that it functions as the "collision cell." It uses a combination of inert gases and changing frequencies. As the ions from the fi rst quadrapole mass spectrometer enter this second chamber, they collide with the inert gases and fragment into even smaller ions. Th ese molecules then enter the third quadrapole, where they are detected. By fragmenting parent ions with similar m/z ratios, new ions are created with diff ering m/z ratios, which are sent and detected in the third quadrapole. Th is functions to identify the parent molecule with great specifi city. Figure 2 . Schematic of a quadrapole mass spectrometer. The quadrapole is set to transmit only ions with a specific mass-to-charge ratio (m/z) that matches the analytes of interest. Because only ions matching the selected m/z are transmitted, the resultant chromatogram and mass spectra are clean and easy to interpret. However, because the two analytes of interest have identical m/z, the mass spectrometer is unable to differentiate between them. Reprinted with permission from Hill et al, 2011 (18) . Figure 3 . Schematic of a mass spectrometer in tandem. Q1 is set to only transmit ions with a specific mass-to-charge ratio (m/z) that matches the analytes of interest. The collision cell, q2, produces fragments from these transmitted ions, while Q3 constantly scans across the entire m/z range, allowing all fragments produced in q2 to reach the detector. The recording of all fragments results in a complex chromatogram and mass spectra but has allowed for the unique identification of each analyte at the appropriate sampled time point, indicated in blue and yellow. Reprinted with permission from Hill et al, 2011 (18) .
